Vifor Pharma

Vifor Pharma EBIT per Employee

Delisted·Dec 22, 2022

The EBIT per Employee of Vifor Pharma (VIFN.SW) as of Nov 5, 2026 is 162,423.08 CHF. In the previous year, EBIT per Employee was 102,538.46 CHF — a change of 58.40% (higher).

EBIT per Employee

162,423.08CHF

YoY

58.40%

Last updated:

EBIT per Employee of Vifor Pharma is 2021 162,423.08 CHF. EBIT per Employee of Vifor Pharma was 2020 102,538.46 CHF. It decreases by 58.40% higher compared to the previous year.

The Vifor Pharma EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2014
138,815.77 CHF
Jan 1, 2015
171,475.00 CHF
Jan 1, 2016
137,014.23 CHF
Jan 1, 2017
51,653.85 CHF
Jan 1, 2018
70,846.15 CHF
Jan 1, 2019
125,000.00 CHF
Jan 1, 2020
102,538.46 CHF
Jan 1, 2021
162,423.08 CHF
The Vifor Pharma EBIT per Employee history
YEAREBIT per EmployeeYoY
162,423.08CHF+58.40%
102,538.46CHF-17.97%
125,000.00CHF+76.44%
70,846.15CHF+37.16%
51,653.85CHF-62.30%
137,014.23CHF-20.10%
171,475.00CHF+23.53%
138,815.77CHF—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

EBIT per Employee of Vifor Pharma is 162,423.08 CHF in 2021.

EBIT per Employee of Vifor Pharma changed from 102,538.46 CHF to 162,423.08 CHF, representing a 58.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's CHF is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Vifor Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Vifor Pharma

All Key Metrics — Vifor Pharma